What factors influence your decision regarding whether to administer a dose-dense chemotherapy regimen in the adjuvant setting to patients with hormone-receptor postive disease?

Many of the studies included in the analyses treated ER+ cases that we would call lower risk using modern genomic testing with adjuvant chemotherapy. So the observed effect of chemotherapy on recurrence and OS in ER+ disease can vary from study to study, depending on the numbers of low vs high risk ...

The disparate results in the two meta-analysis can also be explained by the larger numbers in the current meta-analysis. Moreover, studies with longer follow up are needed in HR-positive breast cancer to evaluate the efficacy of a given chemotherapy with its ovarian function effect.